ACROBIOSYSTEMS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.78 CNY | -0.28% |
|
-5.21% | -34.20% |
| Apr. 24 | Acrobiosystems Co.,Ltd. Proposes Final Cash Dividend for 2023 | CI |
| Apr. 18 | Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 643M 88.7M | Sales 2025 * | 812M 112M | Capitalization | 4.64B 641M |
|---|---|---|---|---|---|
| Net income 2024 * | 188M 25.95M | Net income 2025 * | 254M 35.06M | EV / Sales 2024 * | 7.23 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.72 x |
| P/E ratio 2024 * |
24.7
x | P/E ratio 2025 * |
18.3
x | Employees | 776 |
| Yield 2024 * |
1.83% | Yield 2025 * |
2.31% | Free-Float | 41.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.28% | ||
| 1 week | -5.21% | ||
| Current month | +0.39% | ||
| 1 month | +3.30% | ||
| 3 months | -14.20% | ||
| 6 months | -41.31% | ||
| Current year | -34.20% |
1 week
37.64
40.90
1 month
37.4148.72
Current year
33.0059.25
1 year
33.0074.00
3 years
33.00171.04
5 years
33.00171.04
10 years
33.00171.04
| Managers | Title | Age | Since |
|---|---|---|---|
Yi DIng Chen
CEO | Chief Executive Officer | 47 | 11-02-27 |
Tao Lin
DFI | Director of Finance/CFO | 35 | 19-09-30 |
Jing Yun Miao
BRD | Director/Board Member | 46 | 13-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi DIng Chen
CEO | Chief Executive Officer | 47 | 11-02-27 |
Jing Yun Miao
BRD | Director/Board Member | 46 | 13-01-30 |
Juan Hong Xu
BRD | Director/Board Member | 60 | 20-06-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 38.78 | -0.28% | 1 492 678 |
| 24-05-27 | 38.89 | -0.41% | 2,659,812 |
| 24-05-24 | 39.05 | -0.99% | 2,103,090 |
| 24-05-23 | 39.44 | -2.38% | 2,020,192 |
| 24-05-22 | 40.4 | -0.30% | 2,023,217 |
End-of-day quote Shenzhen S.E., May 27, 2024
More quotes
Acrobiosystems Co Ltd is a China-based company specializing in providing recombinant protein and other key biological reagent products and technical services. The Company's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The Company's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.78
CNY
Average target price
56.78
CNY
Spread / Average Target
+46.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.20% | 643M | |
| +38.59% | 727B | |
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B |
- Stock Market
- Equities
- 301080 Stock
